News for Healthier Living

Gut, Airway and Tumor Microbes Emerge as Promising Predictors of Immunotherapy Response in Lung Cancer

Only 20% to 40% of patients with non small cell lung cancer (NSCLC) respond to immune checkpoint inhibitors, leaving the majority without meaningful clinical benefit. Current biomarkers such as programmed death ligand 1 (PD L1) expression and tumor mutational burden have limited predictive accuracy.

September 9, 2026


September 9 2026

September 8 2026

September 7 2026

September 5 2026

September 4 2026

September 3 2026

September 2 2026

September 1 2026

August 31 2026

August 30 2026

August 29 2026

August 28 2026

August 27 2026

August 26 2026